Warning Letter — Signature Formulations LLC
The FDA's Center for Drug Evaluation and Research issued a Warning Letter to Signature Formulations LLC on October 1, 2026. The source indicates this action followed an inspection or review, though specific violations are not detailed in the excerpt.
This affects Signature Formulations LLC, its manufacturing and quality personnel, and potentially any third-party partners utilizing their formulation or production services.
A Warning Letter from CDER typically signifies significant deviations from Current Good Manufacturing Practice (CGMP) or other regulatory requirements. While the specific nature of the violations is not disclosed in the source, such letters often precede escalated enforcement actions if corrective measures are not documented and implemented promptly. Regulatory professionals should interpret this as an indication of systemic quality system failures at the cited facility.
Regulatory and Quality teams should review the full Warning Letter once available to identify specific CGMP or labeling deficiencies cited. Immediate internal audits of manufacturing sites associated with Signature Formulations LLC are recommended to ensure alignment with CDER expectations.
FDA Warning Letter issued to: Signature Formulations LLC. 10/01/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/signature-formulations-llc-737964-10012026
Open in openFDA / FDA.gov